Tsuyoshi Kaneko, MD: PLO-FLOW TAVR, July Effect, & Alternative Access TAVR
Discussing research related to TAVR with a cardiac surgeon from Brigham and Women's Hospital.
ACC House Call: Tsuyoshi Kaneko, MD, on Late-Breaking TAVR Data
Discussing takeaways from the late-breaking abstracts related to TAVR presented at ACC.20/WCC with a cardiac surgeon from Brigham and Women's Hospital.
Timing of Hormone Replacement Therapy Impacts Outcomes in Older Women
The latest piece coming to us through Notes from Rounds examines how the timing of hormone replacement therapy can impact potential for adverse outcomes.
ACC House Call: Bettering Smoking Cessation Research, Practice
How do e-cigarettes fit into the cardiovascular health paradigm? What more needs to be learned?
Improving Troponin Testing for Myocardial Infarction
New findings show the addition of easily identified circulating proteins can provide a more accurate risk assessment.
ACC House Call: Burnout and COVID-19 with Laxmi Mehta, MD
A discussion on how the COVID-19 outbreak might impact burnout among cardiologists and other medical professionals.
ACC House Call: Laxmi Mehta, MD, on Burnout in Cardiology
Discussing a study examining rates of burnouts in cardiology with lead investigator Laxmi Mehta, MD, director of preventative cardiology and women’s cardiovascular health at Ohio State University.
Notes from Rounds: The State of SGLT2 Inhibitors
A look at the state of cardiometabolic care based on research at ACC.20/WCC from a fourth-year medical student.
ACC House Call: Dapagliflozin for Heart Failure
How new DAPA-HF findings continue to build the SGLT2 inhibitors' cardiovascular portfolio.
ACC House Call: E-Cigarettes for Smoking Cessation
Breaking down the details of the E3 trial, and what more needs to be found in the follow-up.
Sacubitril/Valsartan Reduces NT-proBNP in PARAGON-HF
Patients of both sexes and differing levels of LVEF reported similar reductions in NT-proBNP when treated with the combination therapy, versus lone valsartan.
ACC House Call: PARTNER 3 Takeaways
An interventional cardiologist shares perspective on what the new two-year TAVR findings mean for him and colleagues.
Dapagliflozin Reduces First, Recurrent Event Risk in DAPA-HF
New secondary analsysis from the large-scale heart failure trial shows continued benefit of the SGLT2 inhibitor.
Deepak Bhatt, MD: Impact of EPA Levels on Outcomes in REDUCE-IT
Discussing a REDUCE-IT substudy presented at ACC.20/WCC examining the impact of various EPA levels on outcomes seen in REDUCE-IT.
Ticagrelor Monotherapy Effective for ACS Requiring PCI with Stents
Results of the TICO study support use of ticagrelor monotherapy for patients with ACS requiring PCI with drug-eluting stents.
Vaping Use Associated with Greater Short-Term Cessation than Counseling
New ACC findings show smokers given nicotine or non-nicotine e-cigarettes better in 12-week cessation than those just given counseling.
TWILIGHT-COMPLEX: Ticagrelor Over Dual Antiplatelet Therapy After PCI
Results of a TWILIGHT subanalysis suggest ticagrelor monotherapy might cause less bleeding without increasing events in patients with requiring complex PCI.
Ticagrelor Bests Dual Therapy with Aspirin for Diabetics in TWILIGHT
A new subanalysis from the TWILIGHT trial found benefits of ticagrelor monotherapy remained consistent across both diabetics and nondiabetics.
Apixaban Effective for Treatment of VTE in Cancer Patients
Results of the CARAVAGGIO trial found oral apixaban was noninferior to subcutaneous dalteparin for preventing cancer-associated VTE without increasing a patient’s risk for major bleeding.
Renal Denervation Effective at Reducing Blood Pressure Without Medication
Results of the SPYRAL-HTN OFF MED indicate renal denervation could prove useful for lowering SBP in patients with untreated hypertension.
Concomitant Clopidogrel Shows No Benefit in VOYAGER-PAD Analysis
Marc Bonaca, MD, discusses the results of a subgroup analysis examining the impact of concomitant clopidogrel use in VOYAGER-PAD study.
Rivaroxaban Reduces Post-Surgery VTE Risk by 75% Versus Enoxaparin
New PRONOMOS data shows patients receiving lower limb surgery benefit significant from the oral anticoagulant—without increased risk of bleeding.
POPular-TAVI: Concomitant Antiplatelet Use Increases Bleeding Risk
Results of POPular TAVI indicate concomitant clopidogrel with oral anticoagulants increases risk of bleeding in patients requiring long-term anticoagulation after TAVI.
Low-Risk TAVR Sustains Benefits at 2 Years in PARTNER 3
New trial data shows symptomatic patients with aortic stenosis reported noninferiority in rehospitalization and deaths with the lesser invasive option compared to surgery.
LDL, Systolic Blood Pressure Levels Could Predict Lifetime Cardiovascular Risk
A new ACC 2020 study shows the modifiable levels of CVD risk are distinguishable to long-term event possibility.
ACC House Call: Breaking Down Vericiguat in VICTORIA
A heart failure and transplant cardiologist assesses the new study findings.
ACC House Call: COMPASS Diabetes Insights with Deepak Bhatt, MD
Discussing the impact of rivaroxaban 2.5 mg BID plus aspirin in diabetics versus nondiabetics from the COMPASS trial with Deepak Bhatt, MD.
Add-On Inclisiran Reduces LDL-C by 51% Over 17 Months in ASCVD Patients
Pooled pivotal phase 3 trial data from the ORION program shows the first-in-class therapy's significant benefit and tolerability versus placebo.
ACC House Call: Saturday Late-Breaker Data
A board member of the college highlights 4 highly anticipated trials coming out of ACC 2020.
VOYAGER-PAD Results Detail Benefits of Rivaroxaban Use in PAD Patients
Marc Bonaca, MD, discusses the results of the VOYAGER-PAD trial in a special edition ACC House Call with HCPLive.
